Fiscal year 2025 was strong for UVV, with revenue and operating income up 7% and 5% respectively versus FY24, driven by higher tobacco sales prices despite lower volumes; full-year sales reached $2.95B and operating income was $232.8M.
Q4 FY25 results were impacted by timing shifts in tobacco shipments, resulting in lower sales ($702.3M vs. $770.9M in Q4 FY24) and operating income ($42.8M vs. $68.2M), but SG&A expenses decreased due to lower compensation costs.
Ingredients Operations segment showed improvement, with FY25 operating income rising to $12.3M (from $3.9M in FY24), supported by higher sales volumes and recent investments in platform capabilities; the company is now focused on organic growth and margin improvement in this segment.
Net debt as of 3/31/2025 was $817M, down $180M year-over-year, reflecting strong cash flow and improved working capital management; CapEx for FY26 is projected at $45M–$55M (down from $62M in FY25), and interest expense is expected to decrease due to normalized buying patterns.
For FY26, UVV anticipates strong customer demand in tobacco, with global production expected to increase (flue-cured up 20%, burley up 30%), potentially moving the market toward balance or slight oversupply; the company remains committed to shareholder returns (annualized dividend of $3.28/share) and does not expect material financial impact from the completed Mozambique investigation.